검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DP2 (DS-8201a, DS-8201a (DP2)) Daiichi Sankyo / AstraZeneca·Advanced Solid Tumors ORR 79.7%·t½ 100 days |
|---|---|
Overview Program | DS-8201a (DP2) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Advanced Solid Tumors |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker can inform prognostic decisions in patients at high risk for death from withdrawal of life-sustaini |
PK/PD Half-life | 100 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Quality by Design-Assisted Separation and Characterization of Photolytic Degradation Products of Midostaurin Using UHPLC-Q-TOF-MS/MS: In-Silico Prediction and Toxicity Assessment.. Midostaurin is the first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is susceptible to forming five forced degradation products under photo… |
Clinical Primary efficacy | ORR 79.7% |
Clinical ORR | 79.7% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03529110 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DP2 (DS-8201a, DS-8201a (DP2)) Daiichi Sankyo / AstraZeneca·Advanced Solid Tumors ORR 79.7%·t½ 100 days |
|---|---|
Overview Program | DS-8201a (DP2) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Advanced Solid Tumors |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker can inform prognostic decisions in patients at high risk for death from withdrawal of life-sustaini |
PK/PD Half-life | 100 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Quality by Design-Assisted Separation and Characterization of Photolytic Degradation Products of Midostaurin Using UHPLC-Q-TOF-MS/MS: In-Silico Prediction and Toxicity Assessment.. Midostaurin is the first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is susceptible to forming five forced degradation products under photo… |
Clinical Primary efficacy | ORR 79.7% |
Clinical ORR | 79.7% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03529110 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교